Healthcare/Biotech Analyst Tejavibulya, along with Reneo Pharmaceuticals’ management and Dr. Robert Pitceathly discuss the expectations for Reneo’s Phase 2b data for mavodelpar (PPARdelta agonist) in primary mitochondrial myopathies (PMM) and its commercial opportunity on an Analyst/Industry conference call to be held on November 9 at 3 pm. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RPHM:
- Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
- Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings
- Reneo Pharmaceuticals announces poster presentation on mavodelpar
- Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
- Reneo Pharmaceuticals announces last patient last visit in STRIDE study